Why ObsEva SA (OBSV) stock jumped on Monday?

Published on November 22, 2021 09:08 AM PST

Why ObsEva SA (OBSV) stock jumped on Monday? — Image source: sasirin pamai,Shutterstock

Highlights

FDA has agreed to review the new drug application (NDA) for Linzagolix.

It has set Sep 13, 2022, as a target date for the NDA review under the Prescription Drug User Fee Act (PDUFA).

ObsEva announced the appointment of Stephanie Brown to its Board of Directors.

The ObsEva SA (NASDAQ: OBSV) stocks rallied in premarket trading on Monday after the firm said the US Food and Drug Administration (FDA) has agreed to review its new drug Linzagolix.

Linzagolix manages heavy menstrual bleeding associated with uterine fibroids in premenopausal women. The shares of OBSV traded at US$2.47 at 8:51 am ET on Nov 22, up 6.47% from its closing price of November 19, when it closed at US$2.32, up 5.45%.

The FDA’s consent comes after ObsEva SA submitted its two Phase 3 Primrose trial data. If approved, Linzagolix will be the first and the only GnRH receptor antagonist with extended dosing options for uterine fibroids, the company said.

Also Read: Top rising fintech stocks to explore

FDA has set Sep 13, 2022, as a target action date for the New Drug Application (NDA) review under the Prescription Drug Fee Act (PDUFA).

Also Read: Why did Micron Technology (MU) stock skyrocket on Friday?

What’s next for ObsEva

ObsEva is a Swiss-based clinical-stage biopharmaceutical firm that aims to address some of the unmet needs in women's health. ObsEva was co-founded by Ernest Loumaye in 2012.

CEO Brian O'Callaghan said FDA’s consent is an "important milestone" for the company and the "millions of women" living with uterine fibroids. He expressed optimism about launching the drug in the market soon. In a statement, he added that: “We are encouraged by our positive Phase 3 PRIMROSE results. If approved, we believe Linzagolix will address a significant unmet need in offering a more individualized treatment option for a broader range of women.”

Also Read: Greenland Technologies (GTEC) stock jumps 75% - guess why?

Stock performance and financials

ObsEva has a market cap of US$180.89 million, with a forward P/E one year of US$-2.42. Its EPS is US$-0.85. The stock saw the highest price of US$5.55 and the lowest price of US$1.90 in the last 52 weeks. Its share volume on November 19 was 444,205.

The company reported an operating income of US$1.53 million in Q3, FY21, against a loss of US$23.63 million in the year-ago quarter.

Its net income came in at US$819,000, or US$0.01 per diluted share, versus a loss of US$24.38 million, or a loss of US$0.49 per diluted share in the comparable quarter of the previous year.

Also Read: Intuit Inc. (INTU) raises guidance after earnings, stock jumps

Bottomline

On Monday, the company announced that Stephanie Brown has been selected to join its Board of Directors effective from December 1, 2021. The OBSV stock rose 1.31% YTD.

Rupam Roy

Author

Rupam Roy - Analyst
923 Posts
After completing his graduation in English literature, Rupam briefly worked in content management and digital marketing. At Kalkine, he writes on the US markets. His hobbies include composing songs and music....
Sanjeeb Baruah

Editor

Sanjeeb Baruah - Financial Journalist
368 Posts
Sanjeeb is a senior journalist who has been in the media for nearly two decades. He wrote on various topics, from politics, international relations, business to wildlife. At Kalkine, he writes on stock markets, companies, equities, and IPOs, etc....

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.